Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
722 studies found for:    Open Studies | ovarian cancer
Show Display Options
Rank Status Study
1 Recruiting Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer
Conditions: Ovarian Cancer;   Metastatic Ovarian Cancer
Interventions: Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pembrolizumab
2 Recruiting Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
Conditions: Recurrent Ovarian Cancer;   Platinum Sensitive Ovarian Cancer
Intervention: Drug: Carboplatin
3 Recruiting Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Conditions: Cervical Cancer;   Endometrial Cancer;   Fallopian Tube Cancer;   Hereditary Breast/Ovarian Cancer (brca1, brca2);   Ovarian Cancer;   Sarcoma;   Uterine Leiomyomata;   Vaginal Cancer;   Vulvar Cancer
Interventions: Other: laboratory biomarker analysis;   Other: screening questionnaire administration;   Procedure: study of high risk factors
4 Recruiting Phase II/III Trial of Maintenance Vigil™ for High Risk Stage III/IV Ovarian Cancer
Conditions: Ovarian Cancer;   Ovarian Neoplasms
Interventions: Biological: Vigil;   Biological: Placebo
5 Recruiting Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer
Conditions: Ovarian Cancer;   Ovarian Neoplasms
Interventions: Drug: 18F-EF5 PET/CT scan;   Procedure: Optional biopsy
6 Recruiting PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
Conditions: Ovarian Neoplasms;   Neoplasms, Ovarian;   Ovarian Cancer
Interventions: Drug: Pazopanib;   Drug: Fosbretabulin
7 Recruiting MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer
Conditions: Cancer of Ovary;   Cancer of the Ovary;   Neoplasms, Ovarian;   Ovarian Cancer;   Ovary Cancer;   Ovary Neoplasms
Interventions: Device: MRI-guided SBRT;   Behavioral: EORTC QLQ-C30 Questionnaire;   Behavioral: EORTC QLQ-OV28 Questionnaire
8 Recruiting Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Conditions: Cancer of Ovary;   Cancer of the Ovary;   Neoplasms, Ovarian;   Ovarian Cancer;   Ovary Cancer;   Ovary Neoplasms
Interventions: Biological: Cisplatin + celecoxib + DC vaccine;   Biological: Cisplatin + CKM + Celecoxib + DC Vaccine
9 Recruiting Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
Conditions: Ovarian Cancer;   Cancer of Ovary;   Cancer of the Ovary;   Ovary Neoplasms;   Primary Peritoneal Carcinoma
Intervention: Drug: Fenretinide/LXS + Ketoconazole
10 Recruiting Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer
Conditions: Low-grade Serous Ovarian Carcinoma;   Recurrent Invasive Borderline Serous Ovarian Cancer
Intervention:
11 Recruiting A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Device: ThermalCore Hyperthermia System
12 Not yet recruiting Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199
Conditions: Fallopian Tube Carcinoma;   Hereditary Breast and Ovarian Cancer Syndrome;   Ovarian Carcinoma;   Primary Peritoneal Carcinoma
Interventions: Procedure: Evaluation of Cancer Risk Factors;   Other: Medical Chart Review;   Other: Study of Socioeconomic and Demographic Variables
13 Recruiting A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube;   Primary Peritoneal Cancer;   Recurrent Ovarian Cancer
Interventions: Biological: WT1 Vaccine;   Drug: Nivolumab
14 Recruiting GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer
Conditions: Ovarian Cancer;   Peritoneal Carcinomatosis;   Fallopian Tube Cancer
Intervention: Biological: GL-ONC1
15 Recruiting Mesenchymal Stem Cells (MSC) for Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Genetic: MSC-INFβ;   Behavioral: Questionnaires
16 Unknown  Sentinel Node in Ovarian Cancer
Conditions: Ovarian Cancer;   Sentinel Node
Intervention: Procedure: blue dye and radioactive tracer
17 Recruiting Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer
Conditions: Malignant Neoplasms of Female Genital Organs;   Ovarian Cancer;   Primary Peritoneal Carcinoma;   Fallopian Tube Cancer
Interventions: Drug: Durvalumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Behavioral: Questionnaires;   Procedure: Debulking Surgery
18 Unknown  A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: Lovastatin and Paclitaxel
19 Not yet recruiting PET Imaging of Ovarian Carcinoma With 18F-FSPG
Conditions: Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Radiation: (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG);   Procedure: Positron Emission Tomography;   Other: Laboratory Biomarker Analysis
20 Unknown  Adjuvant Whole Abdominal Intensity Modulated Radiotherapy (IMRT) for High Risk Stage FIGO III Patients With Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Radiation: whole abdomen irradiation using IMRT

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years